Technical Analysis for INVA - Innoviva, Inc.

Grade Last Price % Change Price Change
grade A 19.67 1.03% 0.20
INVA closed up 1.03 percent on Friday, January 18, 2019, on 60 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical INVA trend table...

Date Alert Name Type % Chg
Jan 18 New 52 Week Closing High Bullish 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 NR7-2 Range Contraction 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Up 3 Days in a Row Strength 0.00%
Jan 18 Up 4 Days in a Row Strength 0.00%
Jan 17 New 52 Week Closing High Bullish 1.03%
Jan 17 NR7 Range Contraction 1.03%
Jan 17 Overbought Stochastic Strength 1.03%
Jan 17 Up 3 Days in a Row Strength 1.03%

Older signals for INVA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.
Is INVA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.82
52 Week Low 13.26
Average Volume 1,111,245
200-Day Moving Average 15.4171
50-Day Moving Average 17.4188
20-Day Moving Average 18.0285
10-Day Moving Average 19.227
Average True Range 0.5725
ADX 31.54
+DI 30.6678
-DI 11.0211
Chandelier Exit (Long, 3 ATRs ) 18.1025
Chandelier Exit (Short, 3 ATRs ) 17.2675
Upper Bollinger Band 20.618
Lower Bollinger Band 15.439
Percent B (%b) 0.82
BandWidth 28.726738
MACD Line 0.7136
MACD Signal Line 0.5692
MACD Histogram 0.1444
Fundamentals Value
Market Cap 2.15 Billion
Num Shares 109 Million
EPS 0.80
Price-to-Earnings (P/E) Ratio 24.59
Price-to-Sales 7.61
Price-to-Book 0.00
PEG Ratio 0.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.17
Resistance 3 (R3) 20.16 19.98 20.08
Resistance 2 (R2) 19.98 19.86 19.99 20.05
Resistance 1 (R1) 19.83 19.78 19.91 19.84 20.03
Pivot Point 19.65 19.65 19.69 19.66 19.65
Support 1 (S1) 19.50 19.53 19.58 19.51 19.31
Support 2 (S2) 19.32 19.45 19.33 19.29
Support 3 (S3) 19.17 19.32 19.26
Support 4 (S4) 19.18